Latest & greatest articles for osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoarthritis

521. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis

Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

522. Acupuncture for the pain management of osteoarthritis of the knee

and they did not synthesise the results of studies. Their conclusions may not, therefore, be reliable. Authors' objectives To assess the use of acupuncture in the treatment of osteoarthritis (OA) of the knee. Searching MEDLINE, CINAHL and Alt-Med (from 1977 to 2003) and the Cochrane CENTRAL Register were searched; the search terms were reported. The authors did not state whether they applied any language restrictions to their search strategy. Study selection Study designs of evaluations included (...) of osteoarthritis of the knee. Techniques in Orthopaedics 2003; 18(1): 33-36 Indexing Status Subject indexing assigned by CRD MeSH Acupuncture Analgesia; Arthralgia /therapy; Knee Joint; Osteoarthritis, Knee AccessionNumber 12003006683 Date bibliographic record published 31/08/2005 Date abstract record published 31/08/2005 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results

2003 DARE.

523. Structural and symptomatic efficacy of glucsamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis

Structural and symptomatic efficacy of glucsamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

524. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treament of knee osteoarthritis: a systematic review

osteoarthritis. The available evidence suggested that Hylan G-F 20 injections decreased pain and improved knee function in the short term. The authors' conclusions are supported by the data presented, but differences between included studies, suggest they should be viewed with caution. Authors' objectives To review the efficacy, effectiveness and safety of intra-articular injections of Hylan G-F 20 for the treatment of painful knee osteoarthritis (OA). Searching The manufacturers of Hylan G-F 20 supplied (...) ; n=386): a single course of Hylan G-F 20 produced a significant decrease of painful symptoms of knee OA (as measured on the visual analogue scale), and a short-term improvement in joint function (up to 3 to 6 months post-treatment). The authors noted that significant decreases in symptoms, compared with baseline, were often reported in both the treatment and control groups. Hylan G-F 20 versus NSAIDs and other conventional therapies (3 RCTs; n=407): 2 RCTs found no evidence that intra-articular

2003 DARE.

525. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam

Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac modified-release and piroxicam for 4 weeks, in the treatment of patients with osteoarthritis. The doses studied were 7.5 mg meloxicam once daily, 100 mg diclofenac

2003 NHS Economic Evaluation Database.

526. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis Full Text available with Trip Pro

; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal /adverse effects /economics /therapeutic use; Arthritis, Rheumatoid /drug therapy /physiopathology; Canada; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase Inhibitors /adverse effects /economics /therapeutic use; Drug Costs; Female; Gastrointestinal Diseases /chemically induced; Humans; Lactones /adverse effects /economics /therapeutic use; Male; Markov Chains; Middle Aged; Osteoarthritis /drug therapy /physiopathology; Pyrazoles; Quality (...) The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief

2003 NHS Economic Evaluation Database.

527. Electromagnetic fields for the treatment of osteoarthritis. (Abstract)

Electromagnetic fields for the treatment of osteoarthritis. As the focus for osteoarthritis (OA) treatment shifts away from drug therapy, we consider the effectiveness of pulsed electric stimulation which is proven to stimulate cartilage growth on the cellular level.1)To assess the effectiveness of pulsed electric stimulation for the treatment of osteoarthritis (OA). 2) To assess the most effective and efficient method of applying an electromagnetic field, through pulsed electromagnetic fields (...) reviewers using a validated scale (Jadad 1996). Osteoarthritis outcome measures were extracted from the publications according to OMERACT guidelines (Bellamy 1997) and additional secondary outcomes considered.Only three studies with a total of 259 OA patients were included in the review. Electrical stimulation therapy had a small to moderate effect on outcomes for knee OA, all statistically significant with clinical benefit ranging from 13-23% greater with active treatment than with placebo. Only 2

2002 Cochrane

528. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. (Abstract)

A controlled trial of arthroscopic surgery for osteoarthritis of the knee. Many patients report symptomatic relief after undergoing arthroscopy of the knee for osteoarthritis, but it is unclear how the procedure achieves this result. We conducted a randomized, placebo-controlled trial to evaluate the efficacy of arthroscopy for osteoarthritis of the knee.A total of 180 patients with osteoarthritis of the knee were randomly assigned to receive arthroscopic débridement, arthroscopic lavage (...) , and 51.4+/-23.2, respectively, at two years (P=0.64 and P=0.96, respectively). Furthermore, the 95 percent confidence intervals for the differences between the placebo group and the intervention groups exclude any clinically meaningful difference.In this controlled trial involving patients with osteoarthritis of the knee, the outcomes after arthroscopic lavage or arthroscopic débridement were no better than those after a placebo procedure.

2002 NEJM Controlled trial quality: predicted high

529. Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. Full Text available with Trip Pro

Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. To determine whether a home based exercise programme can improve outcomes in patients with knee pain.Pragmatic, factorial randomised controlled trial of two years' duration.Two general practices in Nottingham.786 men and women aged >/=45 years with self reported knee pain.Participants were randomised to four groups to receive exercise therapy, monthly telephone contact, exercise therapy plus (...) telephone contact, or no intervention. Patients in the no intervention and combined exercise and telephone groups were randomised to receive or not receive a placebo health food tablet.Primary outcome was self reported score for knee pain on the Western Ontario and McMaster universities (WOMAC) osteoarthritis index at two years. Secondary outcomes included knee specific physical function and stiffness (scored on WOMAC index), general physical function (scored on SF-36 questionnaire), psychological

2002 BMJ Controlled trial quality: predicted high

530. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease

S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease Hardy M, Coulter I, Morton SC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Hardy M, Coulter I, Morton SC. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 64. 2002 Authors' objectives This report is a comprehensive literature review and synthesis of evidence on the use of S-adenosyl-L-methionine (SAMe) for the treatment of depression, osteoarthritis, and liver disease. Authors' conclusions These data indicate that SAMe is more

2002 Health Technology Assessment (HTA) Database.

531. Hip resurfacing in patients with osteoarthritis

Hip resurfacing in patients with osteoarthritis Hip resurfacing in patients with osteoarthritis Hip resurfacing in patients with osteoarthritis Bernath V Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bernath V. Hip resurfacing in patients with osteoarthritis. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 9 Authors' objectives This aim (...) of this critical appraisal was to assess how hip resurfacing (Birmingham hip) compares with total hip replacement in improving mobility in patients who have osteoarthritis in the hip. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Arthroplasty; Osteoarthritis, Hip Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton, Victoria 3168, Australia. Tel: +61 3

2002 Health Technology Assessment (HTA) Database.

532. Cox-II inhibitors versus non-steroidal anti-inflammatory drugs in rheumatoid and osteoarthritis patients: gastrointestinal effects

with rheumatoid arthritis or osteoarthritis. Authors' conclusions Identified studies suggest that cox-II inhibitors are associated with a slightly reduced risk of gastrointestinal adverse events compared with NSAIDs. However, the reliability of the conclusion is limited by low power for detecting adverse effects. In many cases, adequate power was achieved by pooling results from different exposure groups (receiving different NSAIDs or different doses). This prevents direct comparison of adverse effects (...) inhibitors was not reported (in the NICE review) or not allowed (in the subsequent RCTs). We cannot, therefore, reliably answer the clinically important question of whether cox-II inhibitors reduce gastrointestinal adverse effects compared with combined therapy with NSAIDs plus H2 antagonists or proton pump inhibitors. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Osteoarthritis Language

2002 Health Technology Assessment (HTA) Database.

533. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis

Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Maetzel A, Krahn M, Naglie G. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Overview Issue 6. 2002 Authors' objectives The purpose of this assessment is to evaluate the long-term cost-effectiveness of the COX2 NSAID celecoxib, in comparison to diclofenac and ibuprofen, and rofecoxib in comparison to naproxen

2002 Health Technology Assessment (HTA) Database.

534. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis

The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Maetzel A, Krahn M, Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report No. 23. 2002 Authors' objectives The purpose of this assessment is to evaluate the long-term cost-effectiveness of the COX2 NSAIDs celecoxib, in comparison to diclofenac and ibuprofen, and rofecoxib in comparison to naproxen

2002 Health Technology Assessment (HTA) Database.

535. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. (Abstract)

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2).To assess the relative therapeutic efficacy of rofecoxib, celecoxib, and acetaminophen in adults with OA.Randomized, parallel-group, double-blind trial, conducted from June 1999 to February 2000, in 29 clinical centers in the United (...) States.Three hundred eighty-two patients aged at least 40 years who had OA of the knee that was previously treated with NSAIDs or acetaminophen.Patients were randomly assigned to receive rofecoxib, 12.5 mg/d (n = 96); rofecoxib, 25 mg/d (n = 95); celecoxib, 200 mg/d (n = 97); or acetaminophen, 4000 mg/d (n = 94) for 6 weeks.Assessments over days 1 to 6 and over 6 weeks included pain on walking, night pain, pain at rest, and morning stiffness as measured on a Western Ontario McMaster Universities

2002 JAMA Controlled trial quality: predicted high

536. Efficacy of balneotherapy for osteoarthritis of the knee: a systematic review

, research should aim to determine the most effective treatment to introduce at the various stages of the disease. Funding Arthritis Society (Canada); Ontario Ministry of Health; Department of Human Resources Development of Canada (Summer Student Program). Bibliographic details Brosseau L, MacLeay L, Robinson V, Casimiro L, Pelland L, Wells G, Tugwell P, McGowan J. Efficacy of balneotherapy for osteoarthritis of the knee: a systematic review. Physical Therapy Reviews 2002; 7(4): 209-222 Other (...) publications of related interest Brosseau L, Robinson V, Pelland L, Casimiro L, Milne S, Judd M et al. Efficacy of balneotherapy in rheumatoid arthritis: a meta-analysis. Phys Ther Rev 2002;7:67-87. Indexing Status Subject indexing assigned by CRD MeSH Arthritis, Rheumatoid /therapy; Balneology; Hydrotherapy; Knee Joint; Osteoarthritis /therapy; Range of Motion, Articular AccessionNumber 12005005093 Date bibliographic record published 31/05/2007 Date abstract record published 31/05/2007 Record Status

2002 DARE.

537. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

) osteoarthritis index (for pain, stiffness and physical function), the American College of Rheumatology (ACR-20) responder index, and joint scores (number of painful or tender swollen joints) for rheumatoid arthritis. For tolerability, the withdrawal rates for adverse effects (at 12 weeks) were reported. For gastrointestinal safety, the incidence of ulcers detected by routine endoscopy (at 12 and 24 weeks) and the incidence of symptomatic ulcers, bleeds, perforations and obstructions (up to 24 weeks) were (...) and control (drug, dose and number randomised), duration, outcome measures for efficacy, and outcome measures used to measure upper gastrointestinal safety. Methods of synthesis How were the studies combined? Separate meta-analyses were undertaken for each comparison and outcome. The efficacy data were analysed separately for osteoarthritis and rheumatoid arthritis, but the two diseases were combined for the analysis of tolerability and safety. Dichotomous data were summarised as a relative risk (RR

2002 DARE.

538. Pulsed signal therapy and the treatment of osteoarthritis

in the review Patients with osteoarthritis were eligible for inclusion. Participants in two of the included studies had osteoarthritis of the knee; in one study patients with osteoarthritis of the cervical spine were included; and in another, patients with cervical and lumbar spondylosis were included. One study was excluded partly because it included patients in the treatment group with different affected joints to those in the control group. Outcomes assessed in the review The inclusion criteria (...) , compared to baseline, at the end of treatment and at the 3- and 6-month follow-ups in patients with cervical or lumbar spondylosis. In the other cohort study (n=34) which had no control group, on average, the pain index decreased from 7.12 to 2.38 from baseline to the one-year follow-up in patients with osteoarthritis of the knee; pain on motion decreased from 7.15 to 1.47 for the same time period. Authors' conclusions The results strongly suggest that PST has an analgesic effect and improves joint

2002 DARE.

539. Effectiveness of psychoeducational interventions in osteoarthritis

included in the review Studies of patients with osteoarthritis were eligible for the review. Some of the included studies evaluated specifically overweight individuals, individuals on low incomes or who lived in inner cities, and community-dwelling adults, as well as those with site-specific osteoarthritis. Studies of patients with rheumatoid arthritis, or a mix of patients with either rheumatoid arthritis or osteoarthritis, were mentioned briefly in the review but were not incorporated (...) Effectiveness of psychoeducational interventions in osteoarthritis Effectiveness of psychoeducational interventions in osteoarthritis Effectiveness of psychoeducational interventions in osteoarthritis Marks R, Allegrante J P Authors' objectives To evaluate the effectiveness of psychoeducational interventions in patients suffering from osteoarthritis. Searching MEDLINE (from 1966 to 2002) and CINAHL (from 1982 to 2002) were searched for studies published as full reports in English; the keywords

2002 DARE.

540. S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease

S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease Hardy M, Coulter I, Morton S C, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig L K, Roth E A, Suttorp M J, Shekelle P Authors' objectives To perform a comprehensive literature review and synthesis of evidence (...) on the use of S-adenosyl-L-methionine (SAMe) for the treatment of depression, osteoarthritis and liver disease. Searching Five extensive searches were conducted of 25 named databases using a search strategy that was provided in an appendix to the review. There were no language restrictions. The reference lists of retrieved articles were searched for additional relevant studies. Study selection Study designs of evaluations included in the review The inclusion criteria specified the inclusion of randomised

2002 DARE.